Picture of Hugel logo

145020 Hugel Share Price

0.000.00%
kr flag iconLast trade - 00:00
HealthcareSpeculativeMid CapHigh Flyer

Momentum

Relative Strength (%)
1m+15%
3m+24.97%
6m+32.33%
1yr+90.94%
Volume Change (%)
10d/3m-15.84%
Price vs... (%)
52w High-7.76%
50d MA+7.84%
200d MA+37.4%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)20.65
PEG Ratio (f)1.94
EPS Growth (f)11.9%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value2.93
Price to Tang. Book3.88
Price to Free Cashflow28.39
Price to Sales6.85
EV to EBITDA15.27

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital12.18%
Return on Equity12.09%
Operating Margin33.22%

Financial Summary

Year End 31st DecUnit201920202021202220232024E2025ECAGR / Avg
Total RevenueKR₩m204,567.63211,038.35231,859.11281,675.14319,699.94385,696452,93511.88%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%-7.66-5.65+36.91+18.17+57.95+3.28+31n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Hugel EPS forecast chart

Profile Summary

Hugel Inc is a Korea-based company mainly engaged in the manufacture of biopharmaceuticals. The Company's product portfolio consists of botulinum toxins which used for treatment of benign essential blepharospasm and temporary improvement of moderate to severe glabellar lines including 50 unit types, 100 unit types and 200unit types; hyaluronic acid (HA) fillers which used for temporary removal of facial wrinkles including the chaeum premium No.1, the chaeum premium No.2, the chaeum premium No.3m the chaeum premium No.4, the chaeum MID 20A, the chaeum DEEP 20A, the chaeum SUB-Q 20A and the chaeum VOLUS 20A; wellages, blue roses and other cosmetics. The Company sells its products in domestic and overseas markets.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
November 22nd, 2001
Public Since
December 24th, 2015
No. of Shareholders
14,841
No. of Employees
126
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
kr flag iconKorea Exchange - KOSDAQ
Shares in Issue
10,842,578

145020 Share Price Performance

Upcoming Events for 145020

Q1 2024 Hugel Inc Earnings Release

Q2 2024 Hugel Inc Earnings Release

Similar to 145020

Picture of AbClon logo

AbClon

kr flag iconKorea Exchange - KOSDAQ

Picture of ADBiotech Co logo

ADBiotech Co

kr flag iconKorea Exchange - KOSDAQ

Picture of Ahn-Gook Pharmaceutical Co logo

Ahn-Gook Pharmaceutical Co

kr flag iconKorea Exchange - KOSDAQ

Picture of Alteogen logo

Alteogen

kr flag iconKorea Exchange - KOSDAQ

Picture of Aminologics Co logo

Aminologics Co

kr flag iconKorea Exchange - KOSDAQ

FAQ